-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DzV6sORR6530hHkytG5yB3sXRNXi0mAOMcFdalG5p3hvRMNhqkImbRLgjo4nvlMn
 mG4BhxVh0Nbs0vXiQkqQ3Q==

<SEC-DOCUMENT>0001144204-05-009694.txt : 20050331
<SEC-HEADER>0001144204-05-009694.hdr.sgml : 20050331
<ACCEPTANCE-DATETIME>20050331155052
ACCESSION NUMBER:		0001144204-05-009694
CONFORMED SUBMISSION TYPE:	NT 10-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20041231
FILED AS OF DATE:		20050331
DATE AS OF CHANGE:		20050331
EFFECTIVENESS DATE:		20050331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARILLO BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001014763
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				751974352
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		NT 10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-04413
		FILM NUMBER:		05720156

	BUSINESS ADDRESS:	
		STREET 1:		800 W 9TH AVE
		CITY:			AMARILLO
		STATE:			TX
		ZIP:			79101-3206
		BUSINESS PHONE:		8063761741

	MAIL ADDRESS:	
		STREET 1:		AMARILLO BIOSCIENCES INC
		STREET 2:		800 W 9TH AVE
		CITY:			AMARILLO
		STATE:			TX
		ZIP:			79101-3206
</SEC-HEADER>
<DOCUMENT>
<TYPE>NT 10-K
<SEQUENCE>1
<FILENAME>v015490nt10-k.txt
<TEXT>
3

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 12b-25
                           NOTIFICATION OF LATE FILING

                                                Commission File Number
                                                                       ---------
(Check One):
            [X] Form 10-K and Form 10-KSB [ ] Form 11-K [ ] Form 20-F
                  [ ] Form 10-Q and Form 10-QSB [ ] Form N-SAR

For Period Ended:                  December 31, 2004
                  --------------------------------------------------------------

[ ] Transition Report on Form 10-K and Form 10-KSB
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q and Form 10-QSB
[ ] Transition Report on Form N-SAR

For the Transition Period Ended:
                                 -----------------------------------------------

      Read Attached Instruction Sheet Before Preparing Form. Please Print or
Type.

      Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

      If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
                                                        ----------------------

- ------------------------------------------------------------------------------

                                     PART I
                             REGISTRANT INFORMATION

    Full name of registrant               AMARILLO BIOSCIENCES, INC.
                              ------------------------------------------------
    Former name if applicable
                              ------------------------------------------------

- ------------------------------------------------------------------------------

    Address of principal executive office (Street and number)
                                                              ----------------
                            4134 Business Park Drive
- ------------------------------------------------------------------------------

    City, state and zip code               Amarillo, Texas 79110
                             -------------------------------------------------


<PAGE>


                                     PART II
                             RULES 12b-25(b) AND (c)

      If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)

      (a)   The reasons described in reasonable detail in Part III of this form
            could not be eliminated without unreasonable effort or expense;

      (b)   The subject annual report, semi-annual report, transition report on
            Form 10-K, 10-KSB, Form 20-F, 11-K, Form N-SAR, or portion thereof
[X]         will be filed on or before the 15th calendar day following the
            prescribed due date; or the subject quarterly report or transition
            report on Form 10-Q, 10-QSB, or portion thereof will be filed on or
            before the fifth calendar day following the prescribed due date; and

      (c)   The accountant's statement or other exhibit required by Rule
            12b-25(c) has been attached if applicable.


                                    PART III
                                    NARRATIVE

      State below in reasonable detail the reasons why Forms 10-K, 10-KSB, 11-K,
20-F, 10-Q, 10-QSB, N-SAR or the transition report or portion thereof, could not
be filed within the prescribed time period.

      Registrant is a small biotech company that has experienced a substantial
reduction in workforce. Registrant currently has only one employee competent to
prepare the Company's financials. The Company changed audit firms and they are
in the process of completing the audit.


                                     PART IV
                                OTHER INFORMATION

      (1) Name and telephone number of person to contact in regard to this
notification.

  Edward L. Morris                   806                       372-2020
- --------------------------------------------------------------------------------
     (Name)                       (Area Code)             (Telephone Number)

      (2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months (or for such shorter) period that the
registrant was required to file such reports) been filed? If answer is no,
identify report(s). [X] Yes [ ] No

      (3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?

                                                             [ ] Yes      [X] No


<PAGE>



      If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.

                             Amarillo Biosciences, Inc.
- --------------------------------------------------------------------------------
                  (Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.


Date: March 31, 2005         By:  /s/ Joseph M. Cummins
- ------------------------     ---------------------------------------------
                                      Joseph M. Cummins, President & CEO

Instruction: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.

                                    ATTENTION

    Intentional misstatements or omissions of fact constitute federal criminal
violations (see 18 U.S.C. 1001).



                              GENERAL INSTRUCTIONS

1.    This form is required by Rule 12b-25 of the General Rules and Regulations
      under the Securities Exchange Act of 1934.

2.    One signed original and four conformed copies of this form and amendments
      thereto must be completed and filed with the Securities and Exchange
      Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the
      General Rules and Regulations under the Act. The information contained in
      or filed with the form will be made a matter of public record in the
      Commission files.

3.    A manually signed copy of the form and amendments thereto shall be filed
      with each national securities exchange on which any class of securities of
      the registrant is registered.

4.    Amendments to the notifications must also be filed on form 12b-25 but need
      not restate information that has been correctly furnished. The form shall
      be clearly identified as an amended notification.

5.    Electronic Filers. This form shall not be used by electronic filers unable
      to timely file a report solely due to electronic difficulties. Filers
      unable to submit a report within the time period prescribed due to
      difficulties in electronic filing should comply with either Rule 201 or
      Rule 202 of Regulation S-T or apply for an adjustment in filing date
      pursuant to Rule 13(b) of Regulation S-T.

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
